ICI-85966: Difference between revisions
No edit summary |
CSV import |
||
| Line 1: | Line 1: | ||
{{Short description|Chemical compound}} | |||
[[File:ICI-85966.svg|thumb|right|Chemical structure of ICI-85966]] | |||
ICI-85966 was developed | '''ICI-85966''' is a chemical compound that was developed as a potential pharmaceutical agent. It is classified as a [[serotonin receptor antagonist]], specifically targeting the [[5-HT2 receptor]] subtype. This compound was investigated for its potential use in treating various conditions related to serotonin dysregulation, such as [[anxiety disorders]], [[depression]], and [[schizophrenia]]. | ||
== | ==Chemical Properties== | ||
ICI-85966 is a synthetic compound with a complex chemical structure. The molecular formula of ICI-85966 is C<sub>21</sub>H<sub>26</sub>ClN<sub>3</sub>O<sub>2</sub>. The compound features a chlorinated aromatic ring, which is a common motif in many pharmacologically active compounds. The presence of nitrogen atoms in its structure suggests that it can form hydrogen bonds, which may influence its binding affinity to the serotonin receptors. | |||
==Pharmacology== | |||
ICI-85966 acts as an antagonist at the 5-HT2 receptor, a subtype of the [[serotonin receptor]] family. The 5-HT2 receptors are G protein-coupled receptors that play a significant role in the modulation of neurotransmission in the central nervous system. By blocking these receptors, ICI-85966 can potentially alter the effects of serotonin, a neurotransmitter involved in mood regulation, perception, and cognition. | |||
== | ===Mechanism of Action=== | ||
The mechanism of action of ICI-85966 involves the inhibition of serotonin binding to the 5-HT2 receptors. This blockade can lead to a decrease in the downstream signaling pathways that are typically activated by serotonin. As a result, the compound may exert anxiolytic and antipsychotic effects, making it a candidate for the treatment of psychiatric disorders. | |||
==Development and Research== | |||
ICI-85966 was developed by [[Imperial Chemical Industries]] (ICI), a company known for its research in pharmaceuticals and chemicals. Although the compound showed promise in preclinical studies, it did not advance to later stages of clinical development. The reasons for this could include insufficient efficacy, undesirable side effects, or strategic business decisions by the developing company. | |||
== | ==Potential Applications== | ||
While ICI-85966 itself may not have reached the market, the research conducted on this compound has contributed to the understanding of serotonin receptor antagonists. Such compounds continue to be of interest in the development of new treatments for mental health disorders. The study of ICI-85966 has provided insights into the design of more effective and selective serotonin receptor antagonists. | |||
==Related Pages== | |||
* [[Serotonin receptor]] | |||
* [[5-HT2 receptor]] | |||
* [[Anxiolytic]] | |||
* [[Antipsychotic]] | |||
* [[Imperial Chemical Industries]] | * [[Imperial Chemical Industries]] | ||
[[Category:Serotonin receptor antagonists]] | |||
[[Category:Experimental drugs]] | |||
Latest revision as of 10:48, 23 March 2025
Chemical compound
ICI-85966 is a chemical compound that was developed as a potential pharmaceutical agent. It is classified as a serotonin receptor antagonist, specifically targeting the 5-HT2 receptor subtype. This compound was investigated for its potential use in treating various conditions related to serotonin dysregulation, such as anxiety disorders, depression, and schizophrenia.
Chemical Properties[edit]
ICI-85966 is a synthetic compound with a complex chemical structure. The molecular formula of ICI-85966 is C21H26ClN3O2. The compound features a chlorinated aromatic ring, which is a common motif in many pharmacologically active compounds. The presence of nitrogen atoms in its structure suggests that it can form hydrogen bonds, which may influence its binding affinity to the serotonin receptors.
Pharmacology[edit]
ICI-85966 acts as an antagonist at the 5-HT2 receptor, a subtype of the serotonin receptor family. The 5-HT2 receptors are G protein-coupled receptors that play a significant role in the modulation of neurotransmission in the central nervous system. By blocking these receptors, ICI-85966 can potentially alter the effects of serotonin, a neurotransmitter involved in mood regulation, perception, and cognition.
Mechanism of Action[edit]
The mechanism of action of ICI-85966 involves the inhibition of serotonin binding to the 5-HT2 receptors. This blockade can lead to a decrease in the downstream signaling pathways that are typically activated by serotonin. As a result, the compound may exert anxiolytic and antipsychotic effects, making it a candidate for the treatment of psychiatric disorders.
Development and Research[edit]
ICI-85966 was developed by Imperial Chemical Industries (ICI), a company known for its research in pharmaceuticals and chemicals. Although the compound showed promise in preclinical studies, it did not advance to later stages of clinical development. The reasons for this could include insufficient efficacy, undesirable side effects, or strategic business decisions by the developing company.
Potential Applications[edit]
While ICI-85966 itself may not have reached the market, the research conducted on this compound has contributed to the understanding of serotonin receptor antagonists. Such compounds continue to be of interest in the development of new treatments for mental health disorders. The study of ICI-85966 has provided insights into the design of more effective and selective serotonin receptor antagonists.
